Advances in cancer gene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and dsRNA nucleic acids

Journal of B.U.ON.

Volumn 12, Issue SUPPL. 1, 2007, Pages

  Wagner, Ernst ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bioresponsive nanosystems; DNA; Epidermal growth factor; Poly inosine cytosine; Polyplexes; siRNA

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 12; LIPOSOME; LISTERIOLYSIN O; MACROGOL; NANOCARRIER; NANOPARTICLE; PLASMID DNA; POLYETHYLENEIMINE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN P53; SMALL INTERFERING RNA; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOCARCINOMA; BIODEGRADABILITY; BREAST CANCER; CANCER GENE THERAPY; CONFERENCE PAPER; DISULFIDE BOND; DRUG RELEASE; DRUG UPTAKE; ELECTROCHEMOTHERAPY; ELECTROPORATION; ENDOSOME; EWING SARCOMA; GENE TRANSFER; GLIOBLASTOMA; HUMAN; INTRACRANIAL TUMOR; MICROBUBBLE; NANOPHARMACEUTICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; TUMOR;

ANIMALS; BIOCOMPATIBLE MATERIALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LIGANDS; MICE; NANOTECHNOLOGY; NEOPLASMS; PLASMIDS; POLYMERS; RECEPTORS, CELL SURFACE; RNA, DOUBLE-STRANDED; RNA, SMALL INTERFERING;

EID: 36749026586     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Felgner PL, Barenholz Y, Behr JP et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997; 8: 511-512.
2. Stopeck AT, Jones A, Hersh EM et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/ beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7: 2285-2291.
3. Bergen M, Chen R, Gonzalez R. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma. Expert Opin Biol Ther 2003; 3: 377-384.
4. Wickham TJ. Ligand-directed targeting of genes to the site of disease. Nat Med 2003; 9: 135-139.
5. Mancheno-Corvo P, Martin-Duque P. Viral gene therapy. Clin Transl Oncol 2006; 8: 858-867.
6. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006; 16: 175-183.
7. Boeckle S, Wagner E. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS J 2006; 8: E731-E742.
8. Wagner E. Strategies to improve DNA polyplexes for in vivo gene transfer: will "artificial viruses" be the answer? Pharm Res 2004; 21: 8-14.
9. Mastrobattista E, van der Aa MA, Hennink WE, Crommelin DJ. Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 2006; 5: 115-121.
10. Saito G, Amidon GL, Lee KD. Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential. Gene Ther 2003; 10: 72-83.
11. Chen CP, Kim JS, Steenblock E, Liu D, Rice KG. Gene transfer with poly-melittin peptides. Bioconjug Chem 2006; 17: 1057-1062.
12. Read ML, Singh S, Ahmed Z et al. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res 2005; 33: e86.
13. Rozema DB, Ekena K, Lewis DL, Loomis AG, Wolff JA. Endosomolysis by Masking of a Membrane-Active Agent (EMMA) for Cytoplasmic Release of Macromolecules. Bioconjug Chem 2003; 14: 51-57.
14. Meyer M, Zintchenko A, Ogris M, Wagner E. A dimethylmaleic acid-melittin-polylysine conjugate with reduced toxicity, pH-triggered endosomolytic activity and enhanced gene transfer potential. J Gene Med 2007 (in press).
15. Ten Hagen TL, Van Der Veen AH, Nooijen PT, Van Tiel ST, Seynhaeve AL, Eggermont AM. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000; 87: 829-837.
16. Viglianti BL, Ponce AM, Michelich CR et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med 2006; 56:1011-1018.
17. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
18. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Bioinspired pH-Responsive Polymers for the Intracellular Delivery of Biomolecular Drugs. Bioconjug Chem 2003; 14: 412-419.
19. Meyer M, Wagner E. pH-responsive shielding of non-viral gene vectors. Expert Opin Drug Deliv 2006; 3: 563-571.
20. Knorr V, Allmendinger L, Walker GF, Paintner FF, Wagner E. An Acetal-Based PEGylation Reagent for pH-Sensitive Shielding of DNA Polyplexes. Bioconjug Chem 2007; 2007 May 4; [Epub ahead of print].
21. Scherer F, Anton M, Schillinger U et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002; 9: 102-109.
22. Xenariou S, Griesenbach U, Ferrari S et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther 2006; 13: 1545-1552.
23. Hauff P, Seemann S, Reszka R et al. Evaluation of gas-filled microparticles and sonoporation as gene delivery system: feasibility study in rodent tumor models. Radiology 2005; 236: 572-578.
24. Hogset A, Prasmickaite L, Selbo PK et al. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev 2004; 56: 95-115.
25. Kloeckner J, Prasmickaite L, Hogset A, Berg K, Wagner E. Photochemically enhanced gene delivery of EGF receptor-targeted DNA polyplexes. J Drug Target 2004; 12: 205-213.
26. Kloeckner J, Boeckle S, Persson D et al. DNA polyplexes based on degradable oligoethylenimine-derivatives: Combination with EGF receptor targeting and endosomal release functions. J Control Release 2006; 116: 115-122.
27. Ndoye A, Dolivet G, Hogset A et al. Eradication of p53-mutated head and neck squamous cell carcinoma xenografts using nonviral p53 gene therapy and photochemical internalization. Mol Ther 2006; 13: 1156-1162.
28. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371-387.
29. Heller LC, Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 2006; 17: 890-897.
30. Schaffer DV, Lauffenburger DA. Targeted synthetic gene delivery Vectors. Curr Opin Mol Ther 2000; 2: 155-161.
31. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release 2003; 91: 173-181.
32. Schatzlein AG. Targeting of Synthetic Gene Delivery Systems. J Biomed Biotechnol 2003; 1: 149-158.
33. Wagner E, Culmsee C, Boeckle S. Targeting of polyplexes: toward synthetic virus vector systems. Adv Genet 2005; 53: 333-354.
34. Russ V, Wagner E. Cell and Tissue Targeting of Nucleic Acids for Cancer Gene Therapy. Pharm Res 2007; 24: 1047-1057.
35. Blessing T, Kursa M, Holzhauser R, Kircheis R, Wagner E. Different strategies for formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. Bioconjug Chem 2001; 12: 529-537.
36. von Gersdorff K, Ogris M, Wagner E. Cryoconserved shielded and EGF receptor targeted DNA polyplexes: cellular mechanisms. Eur J Pharm Biopharm 2005; 60: 279-285.
37. de Bruin K, Ruthardt N, von Gersdorff K et al. Cellular dynamics of EGF receptor-targeted synthetic viruses. Mol Ther 2007; 15: 1297-1305.
38. Wolschek MF, Thallinger C, Kursa M et al. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology 2002; 36: 1106-1114.
39. Brunner S, Furtbauer E, Sauer T, Kursa M, Wagner E. Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Mol Ther 2002; 5: 80-86.
40. ShirA, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med 2006; 3: e6.
41. Boeckle S, Wagner E, Ogris M. C- versus N-terminally linked melittin-polyethylenimine conjugates: the site of linkage strongly influences activity of DNA polyplexes. J Gene Med 2005; 7: 1335-1347.
42. Boeckle S, Fahrmeir J, Roedl W, Ogris M, Wagner E. Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. J Control Release 2006; 112: 240-248.
43. Meyer M, Wagner E. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum Gene Ther 2006; 17: 1062-1076.
44. Hildebrandt IJ, Iyer M, Wagner E, Gambhir SS. Optical imaging of transferrin targeted PEI/DNA complexes in living subjects. Gene Ther 2003; 10: 758-764.
45. Kursa M, Walker GF, Roessler V et al. Novel Shielded Transferrin-Polyethylene Glycol-Polyethylenimine/DNA Complexes for Systemic Tumor-Targeted Gene Transfer. Biocorjug Chem 2003; 14: 222-231.
46. Yu W, Pirollo KF, Rait A et al. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther 2004; 11: 1434-1440.
47. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FL11 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-8992.
48. Schiffelers RM, Ansari A, Xu J et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32: e149.
49. Song E, Zhu P, Lee SK et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23: 709-717.
50. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002; 4: 84-91.
51. Boeckle S, von Gersdorff K, van der Piepen S, Culmsee C, Wagner E, Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med 2004; 6: 1102-1111.
52. Fahrmeir J, Gunther M, Tietze N, Wagner E, Ogris M. Electrophoretic purification of tumor targeted polyethylenimine-based polyplexes reduces toxic side effects in vivo. J Control Release 2007 (in press).
53. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 2005; 11: 990-995.
54. Wagner E, Kloeckner J. Gene delivery using polymer therapeutics. Adv Polym Sci 2006; 192: 135-173.
55. Zhao Z, Wang J, Mao HQ, Leong KW. Polyphosphoesters in drug and gene delivery. Adv Drug Deliv Rev 2003; 55: 483-499.
56. Anderson DG, Akinc A, Hossain N, Langer R. Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters). Mol Ther 2005; 11: 426-434.
57. Thomas M, Ge Q, Lu JJ, Chen J, Klibanov AM. Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm Res 2005; 22: 373-380.
58. Kloeckner J, Bruzzano S, Ogris M, Wagner E. Gene carriers based on hexanediol diacrylate linked oligoethylenimine: effect of chemical structure of polymer on biological properties. Biocorjug Chem 2006; 17: 1339-1345.
59. Zhong Z, Song Y, Engbersen JF, Lok MC, Hennink WE, Feijen J. A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s. J Control Release 2005; 109: 317-329.
60. Kim YH, Park JH, Lee M, Kim YH, Park TG, Kim SW. Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J Control Release 2005; 103: 209-219.
61. Kloeckner J, Wagner E, Ogris M. Degradable gene carriers based on oligomerized polyamines. Eur J Pharm Sci 2006; 29: 414-425.
62. Leng Q, Scaria P, Zhu J, Ambulos N, Campbell P, Mixson AJ. Highly branched HK peptides are effective carriers of siRNA. J Gene Med 2005; 7: 977-986.
63. Tarcha PJ, Pelisek J, Merdan T et al. Synthesis and characterization of chemically condensed oligoethylenimine containing beta-aminopropionamide linkages for siRNA delivery. Biomaterials 2007; 28: 3731-3740.
64. Hoon JJ, Christensen LV, Yockman JW et al. Reducible poly(amido ethylenimine) directed to enhance RNA interference. Biomaterials 2007; 28: 1912-1917.